Bazedoxifene/conjugated estrogens
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause
Trial Timeline
Apr 1, 2007 → Jul 1, 2007
NCT ID
NCT00479778About Bazedoxifene/conjugated estrogens
Bazedoxifene/conjugated estrogens is a phase 1 stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00479778. Target conditions include Postmenopause.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00479778 | Phase 1 | Completed |
| NCT00396799 | Phase 1 | Completed |
Competing Products
16 competing products in Postmenopause